---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-001977"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:02:21.896315+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics appoints Noriyuki Kasahara as Chief Scientific Officer effective Jan 2, 2024

## Summary
- Noriyuki Kasahara, M.D., Ph.D., appointed CSO effective January 2, 2024.
- Kasahara resigned from the Board and as Chair of the Science and Technology Committee on January 1, 2024.
- Resignation not due to any disagreement with the Company or Board.
- He transitions from Board member to executive officer role.

## SEC filing metadata
- accession: 0001193125-24-001977
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/0001193125-24-001977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/d624050d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-001977
- JSON: https://secwatch.observer/filing/0001193125-24-001977.json
- Plain text: https://secwatch.observer/filing/0001193125-24-001977.txt

## Key facts
- Executive change
  Noriyuki Kasahara was appointed as Chief Scientific Officer at 4D Molecular Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) as Chief Scientific Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312524001977/0001193125-24-001977-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.